**2024 Cancer PathCHART ICD-O-3 Site Morphology Validation List v1.0**

***Release Notes***

*(File Date 8/29/2023; Release Date 9/1/2023)*

The Cancer Pathology Coding Histology and Registration Terminology (Cancer PathCHART) initiative is a ground-breaking collaboration of North American and global registrar, registry, pathology, and clinical organizations. The main goal of Cancer PathCHART is to improve cancer surveillance data quality by updating standards for tumor site, histology, and behavior code combinations and associated terminology. This initiative involves a substantial, multifaceted review process of histology and behavior codes (and associated terminology) by tumor site that includes expert pathologists and tumor registrars. The results of these in-depth reviews are incorporated into the Cancer PathCHART database, which serves as the single source of truth standards for tumor site, histology, and behavior coding across all standard setters.

The 2024 Cancer PathCHART ICD-O-3 Site Morphology Validation List (CPC SMVL), output directly from the Cancer PathCHART database, is a comprehensive table that replaces both the ICD-O-3 SEER Site/Histology Validation List and the list of impossible site and histology combinations included in the Primary Site, Morphology-Imposs ICDO3 (SEER IF38) edit. The 2024 CPC SMVL is freely available to cancer registration software vendors and any other end users in easily consumed, computer-readable formats (CSV, XLSX, XML and JSON).

The 2024 CPC SMVL:

1. Has been output from the CPC database and is a single, all-inclusive table with both CPC pathologist-reviewed and remaining unreviewed (i.e., existing) site/histology/behavior combinations
	1. For cases diagnosed in 2023 and earlier, 2023 tumor site and morphology standards will be used (i.e., the ICD-O-3 SEER Site/Histology Validation List updated for 2023)
		1. Standards will **not be applied retroactively**, **no review** **of cases diagnosed prior to 2024** **will be required**
	2. For cases diagnosed in 2024 at sites/organ systems that have **undergone** the **Cancer PathCHART review** processes, **updated 2024 standards** will be used
	3. **For all other cases** diagnosed in 2024 at topographical sites **that have yet to be reviewed**, **2023** tumor site and morphology **standards will be used**
2. No longer includes ranges of codes (for either primary site or histology), eliminating the inclusion of non-existent codes
3. Is a much larger table than the ICD-O-3 SEER Site/Histology Validation List, consisting of a row for each individual ICD-O-3.2 topography, histology and behavior code combination included in the list
4. For pathologist-reviewed site/organ systems, any additional combinations from the WHO Classification of Tumours, 5th Edition series books in print (not online beta versions) are included
5. Includes a validation Status Code for each combination
	1. The Status code is an integer representing the validity of each row's Site, Histology, and Behavior code combinations
	2. The status code values are defined as follows:

1 = Valid

2 = Unlikely (not included)

3 = Impossible

1. The CPC SMVL includes the following columns:

|  |  |
| --- | --- |
| **Column** | **Description** |
| **Key** | An auto-generated unique row identifier, of integer data type, created by: a) Converting the site C-Code into an integer, removing the leading "C" and any leading zerosb) Appending the 4 digit histology code and the 1 digit behavior code |
| **FullKey** | An auto-generated unique row identifier, of string type, created by taking the site code, and appending the 4 digit histology code and the 1 digit behavior code |
| **C\_Site** | The ICD-O-3 topography code that identifies the primary tumor site |
| **Hist** | The 4 digit ICD-O-3.2 histology code |
| **Behavior** | The 1 digitICD-O-3.2 behavior code |
| **Status** | An integer representing the validity of each row's Site, Histology, and Behavior code combinationsThe status code values are as follows:1 = Valid2 = Unlikely (not included in this list. All site-type combinations not appearing in this CPC\_SMVL\_2024 list should be considered status 2 (Unlikely) 3 = Impossible |

1. For cases diagnosed January 1, 2024, and later, the CPC SMVL will serve as the basis for the newly-added Primary Site, Morphology-Type, Beh ICDO3 2024 (N7040) edit, which checks for valid, unlikely and impossible site, histology, behavior combinations.
2. The production release of the 2024 CPC SMVL includes pathologist-reviewed, updated Status for site/histology/behavior combinations for the Site/Organ systems listed in the following table.

|  |  |
| --- | --- |
| **Organ System** | **Sites Reviewed for 2024 Implementation** |
| Digestive | Ampulla of Vater; Anus; Appendix; Biliary System; Colon & Rectum; Esophagus; Gallbladder; Liver; Pancreas; Small Intestine; Stomach |
| Bone & Soft Tissue | Bones & Joints; Connective, Subcutaneous & Other Soft Tissue |
| Breast | Breast |
| Female Genital | Cervix; Endometrium; Fallopian Tube; Myometrium; Ovary; Vagina; Vulva, Adnexa & Other Female Genital; Placenta |
| Male Genital | Penis; Prostate; Testis (90.2% complete) |
| Urinary | Kidney (72.6% complete) |

1. Status for the remaining, unreviewed, site/histology/behavior combinations has been obtained from
	1. Valid Status from the 2023 ICD-O-3 SEER Site/Histology Validation List (updated with 2024 information)
	2. Impossible Status from the current table upon which the Primary Site, Morphology-Imposs ICDO3 (SEER IF38) edit runs
	3. Unreviewed site/histology/behavior combinations not included in the above 2 resources have been assigned a Status of 2 = Unlikely